<DOC>
	<DOCNO>NCT00519701</DOCNO>
	<brief_summary>The purpose study asses prospectively safety efficacy hydroxyurea therapy child Sickle cell Anemia age 18 month 5 year , special emphasis ability hydroxyurea prevent reverse chronic organ damage .</brief_summary>
	<brief_title>Hydroxyurea Young Children With Sickle Cell Anemia</brief_title>
	<detailed_description>Previous study show hydroxyurea therapy adult old child SCA improve laboratory parameter ameliorate clinical severity disease . Little known , however , effect hydroxyurea chronic organ damage occur patient SCA lead significant morbidity mortality young adult . The objective study assess safety efficacy HU young child SCA determine whether HU preserve renal function , reduce transcranial doppler ultrasound ( TCD ) value , prevents development brain ischemia evidence MRI/MRA image . In addition , evaluate effect hydroxyurea quality life</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>Clinical diagnosis Sickle Cell Anemia ( Hb SS Hb S beta zerothalassemia )</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>sickle cell anemia</keyword>
	<keyword>hydroxyurea</keyword>
</DOC>